NCT02239705

Brief Summary

The purpose of this study is to investigate whether cardiac output (CO) and global end diastolic volume (GEDV) determined from the same thermodilution curve by EV1000 are mathematically coupled during the infusion of fluid or inotropic agents in critically ill patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2014

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2014

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

September 10, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 15, 2014

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

September 15, 2014

Status Verified

September 1, 2014

Enrollment Period

2 months

First QC Date

September 10, 2014

Last Update Submit

September 11, 2014

Conditions

Keywords

Trans pulmonary thermodilutionHemodynamic

Outcome Measures

Primary Outcomes (4)

  • Change in Cardiac Output

    To evaluate the change in cardiac function after therapeutic life-saving fluid resuscitation or vasopressor agent infusion, cardiac output will be assessed before and after 20 minutes starting infusion.

    Triplicate measurement in each subject before and 20 minutes after therapeutic infusion of fluids or vasopressor agents

  • Change in Global end diastolic volume

    To evaluate the change in cardiac function after therapeutic life-saving fluid resuscitation or vasopressor agent infusion, global end diastolic volume will be assessed before and after 20 minutes starting infusion.

    Triplicate measurement in each subject before and 20 minutes after therapeutic infusion of fluids or vasopressor agents

  • Change Left ventricular volume

    To evaluate the change in cardiac function after therapeutic, life-saving fluid resuscitation or vasopressor agent infusion, Left ventricular volume measurement with echocardiography will be evaluated before and after 20 minutes starting infusion.

    Before and 20 minutes after therapeutic infusion of fluids or vasopressor agents

  • Change Right ventricular volume

    To evaluate the change in cardiac function after therapeutic life-saving fluid resuscitation or vasopressor agent infusion, Right Ventricular Volume measurement with echocardiography will be assessed before and after 20 minutes starting infusion.

    Before and 20 minutes after therapeutic infusion of fluids or vasopressor agents

Study Arms (2)

Fluid challenge

Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output

Inotropic infusion

Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Critically ill patients

You may qualify if:

  • patient admitted in the Intensive Care Department
  • patient monitored by EV1000 trans pulmonary device
  • Systolic blood pressure (SBP) less than 90 mm Hg or SBP Drop ≥ 40 mm Hg of normal
  • decision by 1 expert intensivist physician to initiate fluid resuscitation hospital protocol or therapeutic infusion of vasopressor agent

You may not qualify if:

  • pregnancy
  • age less than 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ospedali Riuniti

Foggia, FG, 70100, Italy

Location

Related Links

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Michele Dambrosio, Medic

    University of Foggia

    STUDY CHAIR
  • Livio Tullo, Medic

    University of Foggia

    STUDY DIRECTOR
  • Alberto Sciusco, medic

    University of Foggia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alberto Sciusco, Doctor

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical doctor

Study Record Dates

First Submitted

September 10, 2014

First Posted

September 15, 2014

Study Start

September 1, 2014

Primary Completion

November 1, 2014

Study Completion

December 1, 2014

Last Updated

September 15, 2014

Record last verified: 2014-09

Locations